Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Wiener Neustadt – page 48

861 clinical trials in Wiener Neustadt, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Wiener Neustadt at a glance
861
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

861 trials in Wiener Neustadt

Open in trial search

Migraine

Not recruiting

Study on Rimegepant for Treating Migraine in Adults Who Cannot Use Triptans

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Migraine

Not recruiting

Study on Rimegepant for Preventing Migraines in Adults with Poor Response to Oral Preventive Medications

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Study on Ceralasertib and Trastuzumab Deruxtecan for Patients with Non-Small Cell Lung Cancer After Anti-PD-1/PD-L1 Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:Astrazeneca AB

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Uveitis+1

Not recruiting

Study on Izokibep for Patients with Non-infectious Uveitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Izokibep
  • Sponsor:Acelyrin Inc.

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Study of emactuzumab compared to placebo in patients with tenosynovial giant cell tumor

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emactuzumab
  • Sponsor:Synox Therapeutics Limited

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Wiener Neustadt

What the registry says about research in the country

01 Oncology - Digestive System

Groundbreaking research focusing on colorectal cancer treatments, including studies evaluating new combination therapies with immunotherapy agents. Investigations target both MSS/pMMR and KRAS G12C mutations.

  • Metastatic Colorectal Cancer
  • Gastric Cancer
  • Cholangiocarcinoma

Novel therapeutic approaches combining targeted treatments with established protocols.

02 Hematologic Malignancies

Advanced studies in blood cancers, particularly focusing on multiple myeloma and follicular lymphoma. Research includes innovative combination therapies and comparative effectiveness studies.

  • Multiple Myeloma Treatments
  • Lymphoma Therapies
  • Blood Disorders

Emphasis on improving outcomes for newly diagnosed patients and those requiring alternative treatment options.

03 Breast Cancer Research

Innovative trials examining treatments for HER2-negative breast cancer, including studies of new therapeutic agents and combination approaches for both early-stage and metastatic disease.

  • ER+ Breast Cancer
  • Metastatic Disease
  • Adjuvant Therapies

Focus on personalized treatment strategies and targeted therapies.

04 Multi-Cancer Approaches

Comprehensive research involving multiple cancer types, including solid tumors across various organs. Studies evaluate novel therapeutic combinations and immunotherapy approaches.

  • Bladder Cancer
  • Lung Cancer
  • Pancreatic Cancer

Integration of innovative treatment modalities across different cancer types.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.